Medicus Pharma

Medicus Pharma reported Q2 2026 advancements in its SkinJect® and Teverelix® programs, securing FDA authorization for key trials and positive clinical data. The company raised $40 million year-to-date, increasing cash reserves. However, substantial doubt remains about its ability to continue as a going concern without further financing, as operating expenses and net losses widened year-over-year.